Valuation: Silence Therapeutics plc

Market Cap 366M 494M 432M 398M 693M 47.49B 705M 4.75B 1.86B 23.21B 1.85B 1.81B 80.01B P/E 2026 *
-17.5x
P/E 2027 * -15.6x
Enterprise Value 220M 296M 259M 239M 416M 28.49B 423M 2.85B 1.12B 13.92B 1.11B 1.09B 47.99B EV / Sales 2026 *
88x
EV / Sales 2027 * 33.9x
Free-Float
69.36%
Yield 2026 *
-
Yield 2027 * -
1 day+7.18%
1 week+5.03%
Current month-4.83%
1 month+49.29%
3 months+43.54%
6 months+87.95%
Current year+71.88%
1 week 8.91
Extreme 8.91
10.73
1 month 6.52
Extreme 6.52
11.06
Current year 4.19
Extreme 4.19
11.06
1 year 4.19
Extreme 4.19
11.06
3 years 1.97
Extreme 1.97
27.72
5 years 1.97
Extreme 1.97
27.72
10 years 1.97
Extreme 1.97
35
Manager TitleAgeSince
Chief Executive Officer 72 30/11/2025
Director of Finance/CFO 54 31/01/2022
Chief Tech/Sci/R&D Officer - 31/12/2020
Director TitleAgeSince
Director/Board Member 63 20/06/2018
Chairman 72 31/12/2003
Director/Board Member 65 04/05/2025
Date Insider Type Main position Quantity % Market Cap.
07-05Sell 865,112 0.6105%
01-01Free

Chief Technology Officer

300,000 0.2117%
01-01Free

Chief Financial Officer

375,000 0.2646%
Change 5-day change 1-year change 3-year change Capi.($)
+7.18%+5.03%+61.02%+80.17% 494M
-1.46%-1.68%+0.53%+5.84% 50.35B
-0.29%-2.81%+387.81%+591.82% 39.21B
-0.49%+1.48%+31.16%-6.46% 34.52B
+1.53%+3.11%+15.41%+58.54% 34.6B
+1.68%-0.62%+3.30%+27.34% 27.05B
+1.13%-3.11% - - 16.68B
-1.29%-0.52%+69.24%+117.60% 15.11B
-0.55%+0.17%+13.99%+17.33% 13.85B
+2.45%+3.99%+18.20%-30.12% 13.18B
Average +0.98%+1.35%+66.74%+95.79% 24.5B
Weighted average by Cap. +0.09%+0.84%+80.75%+121.31%

Financials

2026 *2027 *
Net sales 2.5M 3.37M 2.94M 2.71M 4.73M 324M 4.81M 32.41M 12.72M 158M 12.64M 12.36M 546M 3.44M 4.64M 4.06M 3.74M 6.52M 447M 6.63M 44.69M 17.53M 218M 17.43M 17.05M 752M
Net income -50.34M -67.9M -59.36M -54.76M -95.38M -6.53B -97.01M -654M -257M -3.19B -255M -249M -11.01B -84.67M -114M -99.84M -92.1M -160M -10.99B -163M -1.1B -431M -5.37B -429M -419M -18.51B
Net Debt -146M -198M -173M -159M -277M -19.01B -282M -1.9B -746M -9.29B -742M -726M -32.02B -249M -336M -294M -271M -473M -32.37B -481M -3.24B -1.27B -15.82B -1.26B -1.24B -54.54B
Logo Silence Therapeutics plc
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Employees
88
Date Price Change Volume
15/07/26 US$10.45 +7.18% 791,970
14/07/26 US$9.750 +4.95% 338,977
13/07/26 US$9.290 +2.20% 233,638
10/07/26 US$9.090 -7.81% 365,407
09/07/26 US$9.860 -0.90% 232,796
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
10.45USD
Average target price
29.17USD
Spread / Average Target
+179.11%

Quarterly revenue - Rate of surprise